Immunic, inc. reports second quarter 2022 financial results and provides corporate update
– initial clinical activity results of imu-935 in psoriasis expected in the fourth quarter – – unblinded safety data from the single and multiple ascending dose parts of phase 1 clinical trial of imu-856 in healthy human subjects expected in the third quarter – – $88.1 million in cash and cash equivalents expected to fund immunic into the fourth quarter of 2023 – – webcast to be held today, august 4, 2022, at 8:00 am et – new york , aug. 4, 2022 /prnewswire/ -- immunic , inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended june 30, 2022 and provided a corporate update. "the second quarter was a period of continued progress in each of our key clinical programs, setting the stage for important data readouts during the second half of this year, including for imu-935, a highly potent and selective oral il-17 inhibitor, and imu-856, an orally available and systemically acting small molecule shown preclinically to regulate intestinal barrier function and regenerate bowel epithelium," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission